{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:55:56Z","timestamp":1790556956057,"version":"4.1.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Epstein-Barr virus (EBV) has evolved complex mechanisms to manipulate the host immune system and epigenetic machinery, enabling it to establish lifelong latent infection within host cells. Emerging evidence strongly indicates that the EBV acts as a main epigenetic manipulator by silencing host regulatory genes, altering host chromatin landscapes and exploiting B-cell biology. Key mechanisms include viral-mediated recruitment of host DNA methyltransferases and histone-modifying enzymes; modulation of host non-coding RNAs and chromatin architectural factors; and targeted disruption of interferon signaling through RNA methylation and restructuring of host chromatin. These integrated processes allow EBV to maintain a lifelong infection in humans, evade both innate and adaptive immunity, and respond to reactivation signals. Understanding the virus-host epigenetic interplay offers new opportunities for therapeutic interventions targeting epigenetic regulators in EBV-associated diseases.<\/jats:p>","DOI":"10.1186\/s13148-026-02181-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:24:24Z","timestamp":1783308264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epstein\u2013Barr Virus\u2013host epigenetic interplay: mechanisms of regulation and therapeutic potential"],"prefix":"10.1186","volume":"18","author":[{"given":"Sanaz","family":"Baghban Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Hosseinzadeh Adli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Bannazadeh Baghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahdat","family":"Poortahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Sarvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2181_CR1","unstructured":"Cancian L. Functional differences between type 1 and type 2 Epstein-Barr virus EBNA-2. Imperial College London. 2011."},{"issue":"9","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1128\/jvi.64.9.4084-4092.1990","volume":"64","author":"J Sample","year":"1990","unstructured":"Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3\u00a0C genes. J Virol. 1990;64(9):4084\u201392.","journal-title":"J Virol"},{"issue":"2","key":"2181_CR3","first-page":"65","volume":"9","author":"T Murata","year":"2023","unstructured":"Murata T. Epstein-Barr virus: the molecular virology and the associated diseases. Fujita Med J. 2023;9(2):65\u201372.","journal-title":"Fujita Med J"},{"issue":"20","key":"2181_CR4","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"key":"2181_CR5","doi-asserted-by":"publisher","unstructured":"Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, et al. Asymptomatic primary infection with Epstein-Barr virus: observations on young adult cases. J Virol. 2017;91(21). https:\/\/doi.org\/10.1128\/jvi.00382-17.\u00a0","DOI":"10.1128\/jvi.00382-17"},{"issue":"7","key":"2181_CR6","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.7150\/jca","volume":"11","author":"R Ayee","year":"2020","unstructured":"Ayee R, Ofori M, Wright E, Quaye O. Epstein Barr virus associated lymphomas and epithelia cancers in humans. J Cancer. 2020;11(7):1737\u201350. https:\/\/doi.org\/10.7150\/jca.","journal-title":"J Cancer"},{"key":"2181_CR7","doi-asserted-by":"crossref","unstructured":"Jafari-Sales A, Shariat A, Bannazadeh-Baghi H, Baradaran B, Jafari B. Prevalence of Epstein-Barr virus and JC virus in tissue samples of gastric cancer, non-malignant, and controls by polymerase chain reaction in northwest Iran. Virus Genes. 2025:1\u20139.","DOI":"10.1007\/s11262-025-02165-z"},{"issue":"1","key":"2181_CR8","first-page":"8175628","volume":"2023","author":"S Mafi","year":"2023","unstructured":"Mafi S, Savadi Oskoee D, Bannazadeh Baghi H, Azadi A, Ahangar Oskouee M. Association of Epstein\u2013Barr Virus (EBV) and Human Endogenous Retroviruses (HERV) with multiple sclerosis in Northwest of Iran. Int J Inflamm. 2023;2023(1):8175628.","journal-title":"Int J Inflamm"},{"key":"2181_CR9","doi-asserted-by":"crossref","unstructured":"Rahimi SB, Hashemi SMA, Poursadeghfard M, Tamaddon G, Jamalidoust M, Daryabor G, Sarvari J. EBV viral load and miR-BART10-3p expression in multiple sclerosis: a case-control study. Multiple Scler Relat Disorders. 2026:107108.","DOI":"10.1016\/j.msard.2026.107108"},{"key":"2181_CR10","doi-asserted-by":"publisher","first-page":"1482329","DOI":"10.3389\/fviro.2024.1482329","volume":"4","author":"F Ebrahimi","year":"2024","unstructured":"Ebrahimi F, Rasizadeh R, Sharaflou S, Aghbash PS, Shamekh A, Jafari-Sales A, Bannazadeh Baghi H. Coinfection of EBV with other pathogens: a narrative review. Front Virol. 2024;4:1482329.","journal-title":"Front Virol"},{"key":"2181_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coviro.2017.07.017","volume":"26","author":"RS Scott","year":"2017","unstructured":"Scott RS. Epstein\u2013Barr virus: a master epigenetic manipulator. Curr Opin Virol. 2017;26:74\u201380.","journal-title":"Curr Opin Virol"},{"issue":"4","key":"2181_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/rmv.1786","volume":"24","author":"T Murata","year":"2014","unstructured":"Murata T, Sato Y, Kimura H. Modes of infection and oncogenesis by the Epstein\u2013Barr virus. Rev Med Virol. 2014;24(4):242\u201353.","journal-title":"Rev Med Virol"},{"key":"2181_CR13","doi-asserted-by":"crossref","unstructured":"Young LS, Arrand JR, Murray PG. EBV gene expression and regulation. In: Human herpesviruses: biology, therapy, and immunoprophylaxis. 2007.","DOI":"10.1017\/CBO9780511545313.028"},{"issue":"5","key":"2181_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/cancers16050991","volume":"16","author":"AS Torne","year":"2024","unstructured":"Torne AS, Robertson ES. Epigenetic mechanisms in latent Epstein-Barr virus infection and associated cancers. Cancers. 2024;16(5):991.","journal-title":"Cancers"},{"issue":"7","key":"2181_CR15","doi-asserted-by":"publisher","first-page":"e70501","DOI":"10.1002\/jmv.70501","volume":"97","author":"L Lyu","year":"2025","unstructured":"Lyu L, Li Q, Wang C. EBV latency programs: molecular and epigenetic regulation and its role in disease pathogenesis. J Med Virol. 2025;97(7):e70501.","journal-title":"J Med Virol"},{"key":"2181_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","volume":"52","author":"R Guo","year":"2022","unstructured":"Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle. Curr Opin Virol. 2022;52:78\u201388.","journal-title":"Curr Opin Virol"},{"key":"2181_CR17","first-page":"18","volume":"1","author":"CH Waddington","year":"1942","unstructured":"Waddington CH. The epigenotype. Endeavour. 1942;1:18\u201320.","journal-title":"Endeavour"},{"issue":"1","key":"2181_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gendis.2018.01.002","volume":"5","author":"Z Jin","year":"2018","unstructured":"Jin Z, Liu Y. DNA methylation in human diseases. Genes Dis. 2018;5(1):1\u20138.","journal-title":"Genes Dis"},{"issue":"8","key":"2181_CR19","first-page":"e90188","volume":"17","author":"H Qasim","year":"2025","unstructured":"Qasim H, Khattab K, Shugaer MA, Varrassi G. Epigenetic dysregulation in neurodegenerative disease: implications for neuropathology and therapy. Cureus. 2025;17(8):e90188.","journal-title":"Cureus"},{"issue":"9","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"e1001114","DOI":"10.1371\/journal.ppat.1001114","volume":"6","author":"M Bergbauer","year":"2010","unstructured":"Bergbauer M, Kalla M, Schmeinck A, G\u00f6bel C, Rothbauer U, Eck S, et al. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog. 2010;6(9):e1001114.","journal-title":"PLoS Pathog"},{"issue":"11\u201312","key":"2181_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/17501911.2024.2345040","volume":"16","author":"G Chen","year":"2024","unstructured":"Chen G, Zhang L, Wang R, Xie Z. Histone methylation in Epstein\u2013Barr virus-associated diseases. Epigenomics. 2024;16(11\u201312):865\u201377.","journal-title":"Epigenomics"},{"issue":"1","key":"2181_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20(1):245.","journal-title":"Genome Biol"},{"issue":"10","key":"2181_CR23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1742-4658.2011.08089.x","volume":"278","author":"F Sato","year":"2011","unstructured":"Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278(10):1598\u2013609.","journal-title":"FEBS J"},{"issue":"1","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13046-022-02319-z","volume":"41","author":"W Huang","year":"2022","unstructured":"Huang W, Li H, Yu Q, Xiao W, Wang DO. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Experimental Clin Cancer Res. 2022;41(1):100.","journal-title":"J Experimental Clin Cancer Res"},{"key":"2181_CR25","doi-asserted-by":"publisher","first-page":"1123975","DOI":"10.3389\/fcell.2023.1123975","volume":"11","author":"A Mangiavacchi","year":"2023","unstructured":"Mangiavacchi A, Morelli G, Orlando V. Behind the scenes: How RNA orchestrates the epigenetic regulation of gene expression. Front Cell Dev Biology. 2023;11:1123975.","journal-title":"Front Cell Dev Biology"},{"key":"2181_CR26","first-page":"e1049","volume":"29","author":"E Papakonstantinou","year":"2024","unstructured":"Papakonstantinou E, Dragoumani K, Chrousos GP, Vlachakis D. Exosomal epigenetics. EMBnet J. 2024;29:e1049.","journal-title":"Exosomal Epigenetics EMBnet J"},{"issue":"6","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/femsre\/fuz023","volume":"43","author":"J Chen","year":"2019","unstructured":"Chen J, Longnecker R. Epithelial cell infection by Epstein\u2013Barr virus. FEMS Microbiol Rev. 2019;43(6):674\u201383.","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"02247","DOI":"10.1128\/jvi","volume":"93","author":"A Chakravorty","year":"2019","unstructured":"Chakravorty A, Sugden B, Johannsen EC. An epigenetic journey: Epstein-Barr virus transcribes chromatinized and subsequently unchromatinized templates during its lytic cycle. J Virol. 2019;93(8):02247\u201318. https:\/\/doi.org\/10.1128\/jvi.","journal-title":"J Virol"},{"issue":"12","key":"2181_CR29","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00253-022-12029-3","volume":"106","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang R, Xie Z. The roles of DNA methylation on the promotor of the Epstein\u2013Barr virus (EBV) gene and the genome in patients with EBV-associated diseases. Appl Microbiol Biotechnol. 2022;106(12):4413\u201326.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s13148-011-0026-6","volume":"2","author":"E Poreba","year":"2011","unstructured":"Poreba E, Broniarczyk JK, Gozdzicka-Jozefiak A. Epigenetic mechanisms in virus-induced tumorigenesis. Clin Epigenet. 2011;2(2):233\u201347.","journal-title":"Clin epigenetics"},{"key":"2181_CR31","doi-asserted-by":"crossref","unstructured":"Tempera I, Lieberman PM, editors. Epigenetic regulation of EBV persistence and oncogenesis. Seminars in cancer biology. Elsevier; 2014.","DOI":"10.1016\/j.semcancer.2014.01.003"},{"issue":"11","key":"2181_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/v12111222","volume":"12","author":"LJ Stanland","year":"2020","unstructured":"Stanland LJ, Luftig MA. The role of EBV-induced hypermethylation in gastric cancer tumorigenesis. Viruses. 2020;12(11):1222.","journal-title":"Viruses"},{"key":"2181_CR33","doi-asserted-by":"crossref","unstructured":"Dworza\u0144ska A, Kliszczewska E, Polz-Dacewicz M. TP53 promoter methylation in EBV-Positive and EBV-Negative gastric cancer-a pilot study. Biomed J Sci Tech Res. 2019;17(5).","DOI":"10.26717\/BJSTR.2019.17.003056"},{"issue":"23","key":"2181_CR34","doi-asserted-by":"publisher","first-page":"13242","DOI":"10.1128\/JVI.01396-07","volume":"81","author":"B Gerle","year":"2007","unstructured":"Gerle B, Koroknai A, Fejer Gr, Bakos A, Banati F, Szenthe K, et al. Acetylated histone H3 and H4 mark the upregulated LMP2A promoter of Epstein-Barr virus in lymphoid cells. J Virol. 2007;81(23):13242\u20137.","journal-title":"J Virol"},{"issue":"4","key":"2181_CR35","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/v5041042","volume":"5","author":"A Arvey","year":"2013","unstructured":"Arvey A, Tempera I, Lieberman PM. Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data. Viruses. 2013;5(4):1042\u201354.","journal-title":"Viruses"},{"issue":"11","key":"2181_CR36","doi-asserted-by":"publisher","first-page":"e1002376","DOI":"10.1371\/journal.ppat.1002376","volume":"7","author":"K Tsai","year":"2011","unstructured":"Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse H-J, Lieberman PM. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog. 2011;7(11):e1002376.","journal-title":"PLoS Pathog"},{"issue":"8","key":"2181_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41564-020-0724-y","volume":"5","author":"R Guo","year":"2020","unstructured":"Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, et al. DNA methylation enzymes and PRC1 restrict B-cell Epstein\u2013Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051\u201363.","journal-title":"Nat Microbiol"},{"issue":"4","key":"2181_CR38","doi-asserted-by":"publisher","first-page":"e01408","DOI":"10.1128\/jvi.01408-25","volume":"100","author":"DE Greaves","year":"2026","unstructured":"Greaves DE, Gabaev I, Williamson JC, Bloor S, Martinez Cuesta S, Matheson NJ, et al. Locus-specific proteomics identifies novel regulators of Epstein-Barr virus lytic reactivation. J Virol. 2026;100(4):e01408\u201325.","journal-title":"J Virol"},{"issue":"8","key":"2181_CR39","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/v13081470","volume":"13","author":"SA Dochnal","year":"2021","unstructured":"Dochnal SA, Francois AK, Cliffe AR. De novo polycomb recruitment: lessons from latent herpesviruses. Viruses. 2021;13(8):1470.","journal-title":"Viruses"},{"key":"2181_CR40","doi-asserted-by":"crossref","unstructured":"Liao Y, Yan J, Kong IY, Li Z, Ding W, Clark S et al. Lysine-specific histone demethylase complex restricts Epstein\u2013Barr virus lytic reactivation. Nat Microbiol. 2025:1\u201315.","DOI":"10.1038\/s41564-025-02165-7"},{"issue":"6","key":"2181_CR41","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/JVI.75.6.2584-2596.2001","volume":"75","author":"D Salamon","year":"2001","unstructured":"Salamon D, Takacs M, Ujvari D, Uhlig H Jr, Minarovits J, Niller HH. Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus. J Virol. 2001;75(6):2584\u201396.","journal-title":"J Virol"},{"issue":"20","key":"2181_CR42","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1002\/j.1460-2075.1994.tb06810.x","volume":"13","author":"D Snudden","year":"1994","unstructured":"Snudden D, Hearing J, Smith P, Gr\u00e4sser F, Griffin B. EBNA-1, the major nuclear antigen of Epstein\u2010Barr virus, resembles \u2018RGG\u2019RNA binding proteins. EMBO J. 1994;13(20):4840\u20137.","journal-title":"EMBO J"},{"issue":"11","key":"2181_CR43","first-page":"4480","volume":"90","author":"KD Robertson","year":"1997","unstructured":"Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood J Am Soc Hematol. 1997;90(11):4480\u20134.","journal-title":"Blood J Am Soc Hematol"},{"issue":"23","key":"2181_CR44","doi-asserted-by":"publisher","first-page":"12494","DOI":"10.1128\/JVI.01705-12","volume":"86","author":"S Ramasubramanyan","year":"2012","unstructured":"Ramasubramanyan S, Kanhere A, Osborn K, Flower K, Jenner RG, Sinclair AJ. Genome-wide analyses of Zta binding to the Epstein-Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J Virol. 2012;86(23):12494\u2013502.","journal-title":"J Virol"},{"issue":"10","key":"2181_CR45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/ng1424","volume":"36","author":"PM Bhende","year":"2004","unstructured":"Bhende PM, Seaman WT, Delecluse H-J, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet. 2004;36(10):1099\u2013104.","journal-title":"Nat Genet"},{"issue":"2","key":"2181_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/JVI.01790-12","volume":"87","author":"CK Wille","year":"2013","unstructured":"Wille CK, Nawandar DM, Panfil AR, Ko MM, Hagemeier SR, Kenney SC. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol. 2013;87(2):935\u201350.","journal-title":"J Virol"},{"issue":"7","key":"2181_CR47","doi-asserted-by":"publisher","first-page":"e1002180","DOI":"10.1371\/journal.ppat.1002180","volume":"7","author":"I Tempera","year":"2011","unstructured":"Tempera I, Klichinsky M, Lieberman PM. EBV latency types adopt alternative chromatin conformations. PLoS Pathog. 2011;7(7):e1002180.","journal-title":"PLoS Pathog"},{"key":"2181_CR48","doi-asserted-by":"publisher","unstructured":"Lupey-Green LN, Caruso LB, Madzo J, Martin KA, Tan Y, Hulse M, Tempera I. PARP1 stabilizes CTCF binding and chromatin structure to maintain Epstein-Barr virus latency type. J Virol. 2018;92(18). https:\/\/doi.org\/10.1128\/jvi.00755-18","DOI":"10.1128\/jvi.00755-18"},{"issue":"8","key":"2181_CR49","doi-asserted-by":"publisher","first-page":"e1001048","DOI":"10.1371\/journal.ppat.1001048","volume":"6","author":"I Tempera","year":"2010","unstructured":"Tempera I, Wiedmer A, Dheekollu J, Lieberman PM. CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog. 2010;6(8):e1001048.","journal-title":"PLoS Pathog"},{"issue":"2","key":"2181_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/1097-0142(19890715)64:2<426::AID-CNCR2820640215>3.0.CO;2-O","volume":"64","author":"C Bartsch","year":"1989","unstructured":"Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer. 1989;64(2):426\u201333.","journal-title":"Cancer"},{"issue":"1","key":"2181_CR51","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1038\/s41598-018-33758-4","volume":"8","author":"W Ahmed","year":"2018","unstructured":"Ahmed W, Tariq S, Khan G. Tracking EBV-encoded RNAs (EBERs) from the nucleus to the excreted exosomes of B-lymphocytes. Sci Rep. 2018;8(1):15438.","journal-title":"Sci Rep"},{"issue":"2","key":"2181_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.biocel.2011.11.007","volume":"44","author":"Z Li","year":"2012","unstructured":"Li Z, Chen X, Li L, Liu S, Yang L, Ma X, et al. EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma. Int J Biochem Cell Biol. 2012;44(2):275\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"2181_CR53","doi-asserted-by":"publisher","first-page":"e01495","DOI":"10.1128\/jvi.01495-21","volume":"96","author":"DN Fachko","year":"2022","unstructured":"Fachko DN, Chen Y, Skalsky RL. Epstein-Barr virus miR-BHRF1-3 targets the BZLF1 3\u2019UTR and regulates the lytic cycle. J Virol. 2022;96(4):e01495\u201321.","journal-title":"J Virol"},{"issue":"17","key":"2181_CR54","doi-asserted-by":"publisher","first-page":"01215","DOI":"10.1128\/jvi","volume":"94","author":"KD Yetming","year":"2020","unstructured":"Yetming KD, Lupey-Green LN, Biryukov S, Hughes DJ, Marendy EM, Miranda JL, Sample JT. The BHLF1 locus of Epstein-Barr virus contributes to viral latency and B-cell immortalization. J Virol. 2020;94(17):01215\u201320. https:\/\/doi.org\/10.1128\/jvi.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1128\/JVI.01995-12","volume":"87","author":"A El-Guindy","year":"2013","unstructured":"El-Guindy A, Ghiassi-Nejad M, Golden S, Delecluse H-J, Miller G. Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J Virol. 2013;87(1):208\u201323.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13578-025-01437-3","volume":"15","author":"B Wang","year":"2025","unstructured":"Wang B, Chung GTY, Shuai Y, Wu M, Ji D, Lung RWM, et al. ebv-sisRNA-3 contributes to the formation of G4-associated R-loop upstream of EBV lytic replication origin in latently infected cells. Cell Biosci. 2025;15(1):91.","journal-title":"Cell Bioscience"},{"issue":"4","key":"2181_CR57","doi-asserted-by":"publisher","first-page":"01706","DOI":"10.1128\/mbio","volume":"12","author":"K Zhang","year":"2021","unstructured":"Zhang K, Zhang Y, Maharjan Y, Sugiokto FG, Wan J, Li R. Caspases switch off the m6A RNA modification pathway to foster the replication of a ubiquitous human tumor virus. MBio. 2021;12(4):01706\u201321. https:\/\/doi.org\/10.1128\/mbio.","journal-title":"MBio"},{"issue":"2","key":"2181_CR58","doi-asserted-by":"publisher","first-page":"e03168","DOI":"10.1128\/mbio.03168-23","volume":"15","author":"FG Sugiokto","year":"2024","unstructured":"Sugiokto FG, Saiada F, Zhang K, Li R. SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication. MBio. 2024;15(2):e03168\u201323.","journal-title":"MBio"},{"issue":"1","key":"2181_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-023-00911-9","volume":"30","author":"D Bose","year":"2023","unstructured":"Bose D, Lin X, Gao L, Wei Z, Pei Y, Robertson ES. Attenuation of IFN signaling due to m6A modification of the host epitranscriptome promotes EBV lytic reactivation. J Biomed Sci. 2023;30(1):18.","journal-title":"J Biomed Sci"},{"issue":"6","key":"2181_CR60","doi-asserted-by":"publisher","first-page":"gkag251","DOI":"10.1093\/nar\/gkag251","volume":"54","author":"Z Wu","year":"2026","unstructured":"Wu Z, Liu Y, Zhou D, He Z, Fiches GN, Park Y, et al. m5C RNA methylation is dysregulated by oncogenic herpesviruses via c-Myc signaling to counteract host antiviral factors. Nucleic Acids Res. 2026;54(6):gkag251.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2181_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.dld.2021.06.004","volume":"54","author":"H Song","year":"2022","unstructured":"Song H, Zhang Y, Liu J, Liu W, Luo B. Activation of DNA methyltransferase 3a by Epstein-Barr nuclear antigen 1 in gastric carcinoma. Dig Liver Disease. 2022;54(7):973\u201383.","journal-title":"Dig Liver Disease"},{"issue":"11","key":"2181_CR62","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1128\/JVI.02682-05","volume":"80","author":"K Shire","year":"2006","unstructured":"Shire K, Kapoor P, Jiang K, Hing MNT, Sivachandran N, Nguyen T, Frappier L. Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation. J Virol. 2006;80(11):5261\u201372.","journal-title":"J Virol"},{"key":"2181_CR63","doi-asserted-by":"publisher","first-page":"725301","DOI":"10.3389\/fcell.2021.725301","volume":"9","author":"Z Liang","year":"2021","unstructured":"Liang Z, Wen C, Jiang H, Ma S, Liu X. Protein arginine methyltransferase 5 functions via interacting proteins. Front Cell Dev Biol. 2021;9:725301.","journal-title":"Front cell Dev biology"},{"key":"2181_CR64","doi-asserted-by":"crossref","unstructured":"Ozawa H, Wang Y, Withers HG, Haratake N, Nakashoji A, Bhattacharya A et al. MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression. Oncogene. 2025:1\u201316.","DOI":"10.1038\/s41388-025-03519-5"},{"issue":"1","key":"2181_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/pathogens1010037","volume":"1","author":"HH Niller","year":"2012","unstructured":"Niller HH, Minarovits J. Similarities between the Epstein-Barr virus (EBV) nuclear protein EBNA1 and the pioneer transcription factor FoxA: is EBNA1 a bookmarking oncoprotein that alters the host cell epigenotype? Pathogens. 2012;1(1):37\u201351.","journal-title":"Pathogens"},{"issue":"5","key":"2181_CR66","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1111\/cas.14370","volume":"111","author":"Y Asakawa","year":"2020","unstructured":"Asakawa Y, Okabe A, Fukuyo M, Li W, Ikeda E, Mano Y, et al. Epstein-Barr virus\u2010positive gastric cancer involves enhancer activation through activating transcription factor 3. Cancer Sci. 2020;111(5):1818\u201328.","journal-title":"Cancer Sci"},{"key":"2181_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","volume":"557","author":"Y Yanagi","year":"2021","unstructured":"Yanagi Y, Okuno Y, Narita Y, Al Masud HA, Watanabe T, Sato Y, et al. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Virology. 2021;557:44\u201354.","journal-title":"Virology"},{"issue":"1","key":"2181_CR68","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s42003-021-02501-7","volume":"4","author":"Y Yang","year":"2021","unstructured":"Yang Y, Ye X, Dai R, Li Z, Zhang Y, Xue W, et al. Phase separation of Epstein-Barr virus EBNA2 protein reorganizes chromatin topology for epigenetic regulation. Commun Biol. 2021;4(1):967.","journal-title":"Commun Biology"},{"issue":"9","key":"2181_CR69","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1128\/jvi.70.9.6020-6028.1996","volume":"70","author":"DY Wu","year":"1996","unstructured":"Wu DY, Kalpana GV, Goff SP, Schubach WH. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5\/Ini1. J Virol. 1996;70(9):6020\u20138.","journal-title":"J Virol"},{"issue":"20","key":"2181_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/jvi.00804-17","volume":"91","author":"F Lu","year":"2017","unstructured":"Lu F, Wiedmer A, Martin KA, Wickramasinghe PJ, Kossenkov AV, Lieberman PM. Coordinate regulation of TET2 and EBNA2 controls the DNA methylation state of latent Epstein-Barr virus. J Virol. 2017. https:\/\/doi.org\/10.1128\/jvi.00804-17.","journal-title":"J Virol"},{"issue":"5","key":"2181_CR71","doi-asserted-by":"publisher","first-page":"01987","DOI":"10.1128\/jvi","volume":"91","author":"CK Wille","year":"2017","unstructured":"Wille CK, Li Y, Rui L, Johannsen EC, Kenney SC. Restricted TET2 expression in germinal center type B cells promotes stringent Epstein-Barr virus latency. J Virol. 2017;91(5):01987\u201316. https:\/\/doi.org\/10.1128\/jvi.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR72","doi-asserted-by":"publisher","first-page":"e1005339","DOI":"10.1371\/journal.ppat.1005339","volume":"12","author":"F Lu","year":"2016","unstructured":"Lu F, Chen H-S, Kossenkov AV, DeWispeleare K, Won K-J, Lieberman PM. EBNA2 drives formation of new chromosome binding sites and target genes for B-cell master regulatory transcription factors RBP-j\u03ba and EBF1. PLoS Pathog. 2016;12(1):e1005339.","journal-title":"PLoS Pathog"},{"issue":"7","key":"2181_CR73","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1128\/JVI.77.7.4261-4272.2003","volume":"77","author":"JS Knight","year":"2003","unstructured":"Knight JS, Lan K, Subramanian C, Robertson ES. Epstein-Barr virus nuclear antigen 3\u00a0C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol. 2003;77(7):4261\u201372.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/pathogens7010031","volume":"7","author":"CT Styles","year":"2018","unstructured":"Styles CT, Paschos K, White RE, Farrell PJ. The cooperative functions of the EBNA3 proteins are central to EBV persistence and latency. Pathogens. 2018;7(1):31.","journal-title":"Pathogens"},{"issue":"15","key":"2181_CR75","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1093\/nar\/gks391","volume":"40","author":"K Paschos","year":"2012","unstructured":"Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ. BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res. 2012;40(15):7233\u201346.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2181_CR76","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1128\/JVI.76.10.4699-4708.2002","volume":"76","author":"C Subramanian","year":"2002","unstructured":"Subramanian C, Hasan S, Rowe M, Hottiger M, Orre R, Robertson ES. Epstein-Barr virus nuclear antigen 3\u00a0C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3\/HAT domains and cooperate in regulation of transcription and histone acetylation. J Virol. 2002;76(10):4699\u2013708.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR77","doi-asserted-by":"publisher","first-page":"e1007514","DOI":"10.1371\/journal.ppat.1007514","volume":"15","author":"S Zhang","year":"2019","unstructured":"Zhang S, Pei Y, Lang F, Sun K, Singh RK, Lamplugh ZL, et al. EBNA3C facilitates RASSF1A downregulation through ubiquitin-mediated degradation and promoter hypermethylation to drive B-cell proliferation. PLoS Pathog. 2019;15(1):e1007514.","journal-title":"PLoS Pathog"},{"key":"2181_CR78","doi-asserted-by":"crossref","unstructured":"Iqbal MO, Wang Q, Khan IA, Gu Y, Wu X, Chen J. Ras association domain family member 1 (RASSF1): molecular characteristics, clinical relevance and therapeutic interventions in cancer. Biochimica et Biophysica Acta (BBA)-Mol Basis Disease. 2025;1871:167977.","DOI":"10.1016\/j.bbadis.2025.167977"},{"issue":"18","key":"2181_CR79","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1128\/JVI.00468-11","volume":"85","author":"S Leonard","year":"2011","unstructured":"Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray PG, Woodman CB. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin\u2019s lymphoma. J Virol. 2011;85(18):9568\u201377.","journal-title":"J Virol"},{"issue":"24","key":"2181_CR80","doi-asserted-by":"publisher","first-page":"11668","DOI":"10.1158\/0008-5472.CAN-06-2194","volume":"66","author":"C-L Tsai","year":"2006","unstructured":"Tsai C-L, Li H-P, Lu Y-J, Hsueh C, Liang Y, Chen C-L, et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH2-terminal kinase signaling. Cancer Res. 2006;66(24):11668\u201376.","journal-title":"Cancer Res"},{"issue":"7","key":"2181_CR81","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1158\/0008-5472.CAN-08-3070","volume":"69","author":"R Hino","year":"2009","unstructured":"Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009;69(7):2766\u201374.","journal-title":"Cancer Res"},{"issue":"8","key":"2181_CR82","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1111\/cas.14978","volume":"112","author":"W Li","year":"2021","unstructured":"Li W, Okabe A, Usui G, Fukuyo M, Matsusaka K, Rahmutulla B, et al. Activation of EHF via STAT3 phosphorylation by LMP2A in Epstein-Barr virus\u2013positive gastric cancer. Cancer Sci. 2021;112(8):3349\u201362.","journal-title":"Cancer Sci"},{"issue":"4","key":"2181_CR83","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cell.2015.01.015","volume":"160","author":"N Lee","year":"2015","unstructured":"Lee N, Moss WN, Yario TA, Steitz JA. EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA. Cell. 2015;160(4):607\u201318.","journal-title":"Cell"},{"issue":"9","key":"2181_CR84","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/bies.201500060","volume":"37","author":"N Lee","year":"2015","unstructured":"Lee N, Steitz JA. Noncoding RNA-guided recruitment of transcription factors: a prevalent but undocumented mechanism? BioEssays. 2015;37(9):936\u201341.","journal-title":"BioEssays"},{"key":"2181_CR85","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3389\/fonc.2019.01120","volume":"9","author":"RJ Verhoeven","year":"2019","unstructured":"Verhoeven RJ, Tong S, Mok BW-Y, Liu J, He S, Zong J, et al. Epstein-Barr virus BART long non-coding RNAs function as epigenetic modulators in nasopharyngeal carcinoma. Front Oncol. 2019;9:1120.","journal-title":"Front Oncol"},{"issue":"3","key":"2181_CR86","doi-asserted-by":"publisher","first-page":"e00655","DOI":"10.1128\/mbio.00655-22","volume":"13","author":"RH Edwards","year":"2022","unstructured":"Edwards RH, Raab-Traub N. Major role for cellular MicroRNAs, Long Noncoding RNAs (lncRNAs), and the Epstein-Barr virus-encoded BART lncRNA during tumor growth in vivo. MBio. 2022;13(3):e00655\u201322.","journal-title":"MBio"},{"issue":"14","key":"2181_CR87","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1128\/JVI.00613-16","volume":"90","author":"RJ Verhoeven","year":"2016","unstructured":"Verhoeven RJ, Tong S, Zhang G, Zong J, Chen Y, Jin D-Y, et al. NF-\u03baB signaling regulates expression of Epstein-Barr virus BART microRNAs and long noncoding RNAs in nasopharyngeal carcinoma. J Virol. 2016;90(14):6475\u201388.","journal-title":"J Virol"},{"issue":"1","key":"2181_CR88","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12935-021-01986-w","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y, Hu Z, Zhang Y, Wang C. Long non-coding RNAs in Epstein\u2013Barr virus-related cancer. Cancer Cell Int. 2021;21(1):278.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"2181_CR89","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1084\/jem.20072581","volume":"205","author":"EY-W Choy","year":"2008","unstructured":"Choy EY-W, Siu K-L, Kok K-H, Lung RW-M, Tsang CM, To K-F, et al. An Epstein-Barr virus\u2013encoded microRNA targets PUMA to promote host cell survival. J Exp Med. 2008;205(11):2551\u201360.","journal-title":"J Exp Med"},{"issue":"9","key":"2181_CR90","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/emboj.2012.63","volume":"31","author":"KJ Riley","year":"2012","unstructured":"Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J. 2012;31(9):2207\u201321.","journal-title":"EMBO J"},{"key":"2181_CR91","doi-asserted-by":"publisher","first-page":"116335","DOI":"10.1016\/j.lfs.2019.03.040","volume":"231","author":"Q-M Wang","year":"2019","unstructured":"Wang Q-M, Lian G-Y, Song Y, Huang Y-F, Gong Y. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335.","journal-title":"Life Sci"},{"issue":"1","key":"2181_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12985-020-01308-y","volume":"17","author":"J Zhang","year":"2020","unstructured":"Zhang J, Li X, Hu J, Cao P, Yan Q, Zhang S, et al. Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis. Virol J. 2020;17(1):51.","journal-title":"Virol J"},{"issue":"11","key":"2181_CR93","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/leu.2012.108","volume":"26","author":"P Rosato","year":"2012","unstructured":"Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, et al. Differential regulation of miR-21 and miR-146a by Epstein\u2013Barr virus-encoded EBNA2. Leukemia. 2012;26(11):2343\u201352.","journal-title":"Leukemia"},{"key":"2181_CR94","doi-asserted-by":"publisher","unstructured":"Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, West MJ. Enhancer control of microRNA miR-155 expression in Epstein-Barr virus-infected B cells. J Virol. 2018;92(19). https:\/\/doi.org\/10.1128\/jvi.00716-18.","DOI":"10.1128\/jvi.00716-18"},{"issue":"20","key":"2181_CR95","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.1093\/nar\/gkn666","volume":"36","author":"G Gatto","year":"2008","unstructured":"Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein\u2013Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-\u03baB pathway. Nucleic Acids Res. 2008;36(20):6608\u201319.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2181_CR96","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Therapy. 2024;9(1):332.","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"2181_CR97","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/ijc.27439","volume":"131","author":"K Hui","year":"2012","unstructured":"Hui K, Ho DN, Tsang C, Middeldorp JM, Tsao GS, Chiang AK. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1930\u201340.","journal-title":"Int J Cancer"},{"issue":"1","key":"2181_CR98","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ijc.29698","volume":"138","author":"KF Hui","year":"2016","unstructured":"Hui KF, Cheung AKL, Choi CK, Yeung PL, Middeldorp JM, Lung ML, et al. Inhibition of class I histone deacetylases by romidepsin potently induces E pstein-B arr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int J Cancer. 2016;138(1):125\u201336.","journal-title":"Int J Cancer"},{"issue":"4","key":"2181_CR99","first-page":"1008","volume":"119","author":"SK Ghosh","year":"2012","unstructured":"Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood J Am Soc Hematol. 2012;119(4):1008\u201317.","journal-title":"Blood J Am Soc Hematol"},{"issue":"20","key":"2181_CR100","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","volume":"7","author":"B Haverkos","year":"2023","unstructured":"Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study. Blood Adv. 2023;7(20):6339\u201350.","journal-title":"Blood Adv"},{"key":"2181_CR101","doi-asserted-by":"publisher","first-page":"932914","DOI":"10.3389\/fphar.2022.932914","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Hong JH, Ning Z, Pan D, Fu X, Lu X, Tan J. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol. 2022;13:932914.","journal-title":"Front Pharmacol"},{"key":"2181_CR102","doi-asserted-by":"publisher","first-page":"608304","DOI":"10.3389\/fonc.2020.608304","volume":"10","author":"Z Yan","year":"2020","unstructured":"Yan Z, Yao S, Liu Y, Zhang J, Li P, Wang H, et al. Durable response to sintilimab and chidamide in a patient with pegaspargase-and immunotherapy-resistant NK\/T-cell lymphoma: case report and literature review. Front Oncol. 2020;10:608304.","journal-title":"Front Oncol"},{"issue":"11","key":"2181_CR103","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang Y-J. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Exp Opin Drug Saf. 2020;19(11):1505\u201311.","journal-title":"Exp Opin Drug Saf"},{"issue":"3","key":"2181_CR104","doi-asserted-by":"publisher","first-page":"e26218","DOI":"10.1002\/pbc.26218","volume":"64","author":"RT Kurmasheva","year":"2017","unstructured":"Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2017;64(3):e26218.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2181_CR105","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/epi.14.23","volume":"6","author":"MT McCabe","year":"2014","unstructured":"McCabe MT, Creasy CL. EZH2 as a potential target in cancer therapy. Epigenomics. 2014;6(3):341\u201351.","journal-title":"Epigenomics"},{"issue":"6","key":"2181_CR106","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1128\/msphere.00478-18","volume":"3","author":"T Ichikawa","year":"2018","unstructured":"Ichikawa T, Okuno Y, Sato Y, Goshima F, Yoshiyama H, Kanda T, et al. Regulation of Epstein-Barr virus life cycle and cell proliferation by histone H3K27 methyltransferase EZH2 in Akata cells. Msphere. 2018. https:\/\/doi.org\/10.1128\/msphere.00478-18.\u00a0","journal-title":"Msphere"},{"issue":"2","key":"2181_CR107","first-page":"363","volume":"21","author":"N Sepehrvand","year":"2010","unstructured":"Sepehrvand N, Khameneh ZR, Eslamloo HR. Survey the seroprevalence of CMV among hemodialysis patients in Urmia, Iran. Saudi J Kidney Dis Transpl. 2010;21(2):363\u20137.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"1","key":"2181_CR108","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"2181_CR109","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","volume":"15","author":"DJ Stewart","year":"2009","unstructured":"Stewart DJ, Issa J-P, Kurzrock R, Nunez MI, Jelinek J, Hong D, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15(11):3881\u20138.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2181_CR110","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","volume":"27","author":"PD Zavras","year":"2021","unstructured":"Zavras PD, Shastri A, Goldfinger M, Verma AK, Saunthararajah Y. Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions. Clin Cancer Res. 2021;27(24):6653\u201361.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2181_CR111","first-page":"1870","volume":"135","author":"T Dalton","year":"2020","unstructured":"Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood J Am Soc Hematol. 2020;135(21):1870\u201381.","journal-title":"Blood J Am Soc Hematol"},{"key":"2181_CR112","doi-asserted-by":"publisher","first-page":"106616","DOI":"10.1016\/j.bioorg.2023.106616","volume":"137","author":"S Ciaco","year":"2023","unstructured":"Ciaco S, Mazzoleni V, Javed A, Eiler S, Ruff M, Mousli M, et al. Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells. Bioorg Chem. 2023;137:106616.","journal-title":"Bioorg Chem"},{"issue":"1","key":"2181_CR113","doi-asserted-by":"publisher","first-page":"5","DOI":"10.31557\/APJCP.2025.26.1.5","volume":"26","author":"SJ Sinha","year":"2025","unstructured":"Sinha SJ, Kumar B, Prasad CP, Chauhan SS, Kumar M. Emerging research and future directions on doxorubicin: a snapshot. Asian Pac J Cancer Prevention: APJCP. 2025;26(1):5.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"6","key":"2181_CR114","doi-asserted-by":"publisher","first-page":"e1007796","DOI":"10.1371\/journal.ppat.1007796","volume":"15","author":"F Lang","year":"2019","unstructured":"Lang F, Singh RK, Pei Y, Zhang S, Sun K, Robertson ES. EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis. PLoS Pathog. 2019;15(6):e1007796.","journal-title":"PLoS Pathog"},{"issue":"4","key":"2181_CR115","doi-asserted-by":"publisher","first-page":"e50128","DOI":"10.15252\/embr.202050128","volume":"22","author":"TL Xia","year":"2021","unstructured":"Xia TL, Li X, Wang X, Zhu YJ, Zhang H, Cheng W, et al. N (6)-methyladenosine\u2010binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. EMBO Rep. 2021;22(4):e50128.","journal-title":"EMBO Rep"},{"issue":"1","key":"2181_CR116","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/v17010110","volume":"17","author":"FG Sugiokto","year":"2025","unstructured":"Sugiokto FG, Li R. Targeting EBV episome for anti-cancer therapy: emerging strategies and challenges. Viruses. 2025;17(1):110.","journal-title":"Viruses"},{"issue":"7","key":"2181_CR117","doi-asserted-by":"publisher","first-page":"e00795","DOI":"10.1128\/mbio.00795-24","volume":"15","author":"FG Sugiokto","year":"2024","unstructured":"Sugiokto FG, Li R. Targeted eradication of EBV-positive cancer cells by CRISPR\/dCas9-mediated EBV reactivation in combination with ganciclovir. Mbio. 2024;15(7):e00795\u201324.","journal-title":"Mbio"},{"issue":"1","key":"2181_CR118","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1038\/s41467-024-48031-8","volume":"15","author":"M Wu","year":"2024","unstructured":"Wu M, Hau PM, Li L, Tsang CM, Yang Y, Taghbalout A, et al. Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers. Nat Commun. 2024;15(1):3729.","journal-title":"Nat Commun"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02181-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02181-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02181-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:02:31Z","timestamp":1790553751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02181-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02181-2","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"173"}}